New Posts New Posts RSS Feed - Good News for PDL1+ MBC Patients
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Good News for PDL1+ MBC Patients

 Post Reply Post Reply
Bestbird View Drop Down

Joined: Jan 09 2017
Location: UT
Status: Offline
Points: 6
Post Options Post Options   Thanks (0) Thanks(0)   Quote Bestbird Quote  Post ReplyReply Direct Link To This Post Topic: Good News for PDL1+ MBC Patients
    Posted: Mar 11 2019 at 12:46pm



Good news!  TNBC MBC patients whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells of any intensity covering ≥ 1% of the tumor area) may be eligible to receive Atezolizumab (Tecentriq) with Abraxane. 

Atezolizumab is an immunotherapy drug that works well in combination with chemotherapy. Atezolizumab was closely studied in the IMPassion130 trial, which determined that TNBC MBC patients whose tumors expressed PD-L1 had a median Overall Survival of at least 25 months on Atezolizumab with Abraxane, vs. 15.5 months on Abraxane alone.  As a result, in March 2019 the FDA granted accelerated approval to Atezolizumab in combination with Abraxane for TNBC patients with unresectable locally advanced or metastatic disease whose tumors express PD-L1.  The FDA has also approved the VENTANA PD-L1 (SP142) Assay as a companion diagnostic device for selecting TNBC patients for this therapy. From:

This newly-released information has been incorporated into my book, “The Insider’s Guide to Metastatic Breast Cancer” which is available in paperback and eBook formats on Amazon at X   A complimentary .pdf is available by emailing me at




Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 12.01
Copyright ©2001-2018 Web Wiz Ltd.